CA2687385A1 - New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use - Google Patents

New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use Download PDF

Info

Publication number
CA2687385A1
CA2687385A1 CA002687385A CA2687385A CA2687385A1 CA 2687385 A1 CA2687385 A1 CA 2687385A1 CA 002687385 A CA002687385 A CA 002687385A CA 2687385 A CA2687385 A CA 2687385A CA 2687385 A1 CA2687385 A1 CA 2687385A1
Authority
CA
Canada
Prior art keywords
treated
rats
results
rats treated
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002687385A
Other languages
English (en)
French (fr)
Inventor
Xavier Leverve
Nellie Taleux
Roland Favier (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Joseph Fourier University
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2687385A1 publication Critical patent/CA2687385A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002687385A 2007-05-16 2008-05-16 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use Abandoned CA2687385A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290635.7 2007-05-16
EP07290635A EP1992341A1 (en) 2007-05-16 2007-05-16 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
PCT/EP2008/056076 WO2008138995A1 (en) 2007-05-16 2008-05-16 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use

Publications (1)

Publication Number Publication Date
CA2687385A1 true CA2687385A1 (en) 2008-11-20

Family

ID=38562932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002687385A Abandoned CA2687385A1 (en) 2007-05-16 2008-05-16 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use

Country Status (7)

Country Link
US (1) US20110064773A1 (enExample)
EP (2) EP1992341A1 (enExample)
JP (1) JP2010526858A (enExample)
CN (1) CN103282031A (enExample)
BR (1) BRPI0811636A2 (enExample)
CA (1) CA2687385A1 (enExample)
WO (1) WO2008138995A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
WO2013006402A1 (en) * 2011-07-01 2013-01-10 Thomas Najarian Methods and compositions for facilitating weight loss by administration of thyroid hormones
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
CN108037276A (zh) * 2017-11-28 2018-05-15 泰州泽成生物技术有限公司 磁微粒化学发光法测定rT3含量的试剂盒及其检测方法
JP7840272B2 (ja) * 2020-05-21 2026-04-03 イクイリブレイト セラピューティクス， エルエルシー 甲状腺ホルモンレベルを制御するためのマイクロニードルデバイス
CN116270581A (zh) * 2023-02-28 2023-06-23 山东大学 碘塞罗宁在制备治疗动脉粥样硬化药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
EP2068858A1 (en) * 2007-05-16 2009-06-17 Université Joseph Fourier New pharmaceutical compositions comprising diiodothyronine and their therapeutic use

Also Published As

Publication number Publication date
WO2008138995A1 (en) 2008-11-20
CN103282031A (zh) 2013-09-04
BRPI0811636A2 (pt) 2014-11-11
JP2010526858A (ja) 2010-08-05
US20110064773A1 (en) 2011-03-17
EP2068859A1 (en) 2009-06-17
EP1992341A1 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
Owen et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
US20230285329A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
KR100533618B1 (ko) 당뇨병 치료를 위한 방법 및 조성물
Veech The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism
Wilson Regulation of vitamin C transport
Cettour-Rose et al. Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion
Poucheret et al. Vanadium and diabetes
Casirola et al. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice
Leclercq et al. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARγ agonist pioglitazone
US20110064773A1 (en) pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
US20120053240A1 (en) Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
US10137099B2 (en) Activation of AMP-protein activated kinase by oxaloacetate compounds
MX2015005368A (es) Composiciones, metodos y usos para el tratamiento de la diabetes y afecciones relacionadas controlando el nivel de glucosa en sangre.
Latham et al. Neuroprotective effects of carnitine and its potential application to ameliorate neurotoxicity
Moke et al. Co-administration of metformin and/or glibenclamide with losartan reverse NG-nitro-l-arginine-methyl ester-streptozotocin-induced hypertensive diabetes and haemodynamic sequelae in rats
WO2005009433A1 (en) Use of 3,5 diiodothyronine as regulators of lipid metabolism
US9629896B2 (en) Composition including the HIP/PAP protein or one of the derivatives thereof for treating insulin resistance
US20110028554A1 (en) pharmaceutical compositions comprising diiodothyronine and their therapeutic use
RU2360671C2 (ru) Применение альфа-кетоглутаровой кислоты для лечения недостаточности питания или состояния с высоким уровнем глюкозы в плазме
Alva-Sánchez et al. The long-term regulation of food intake and body weight depends on the availability of thyroid hormones in the brain
Vazquez et al. Regulation of leucine catabolism by caloric sources. Role of glucose and lipid in nitrogen sparing during nitrogen deprivation.
CN1822827B (zh) α-酮戊二酸用于治疗营养不良或高血浆葡萄糖症状的用途
EP3043788B1 (en) D-glyceric acid or dl-glyceric acid for use in the treatment of degeneration diseases related to aging
Munzuroğlu et al. Nitric oxide plays a role in anxiety-and depression-like behaviors induced by sodium metabisulfite intake in rats
Weissman et al. Starvation

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140516